Gujarat Themis Biosyn financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹43.8cr+22.1% on Q1 FY26
Net profit
₹11.1cr+22.1% on Q1 FY26
EBITDA margin
47.5%+8.7 pts on Q1 FY26
EPS
₹1.02+22.9% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue43.835.9+22.1%
EBITDA20.813.9+49.4%
EBITDA margin47.5%38.8%+8.7 pts
Profit before tax15.212.1+25.1%
Net profit11.19.1+22.1%
EPS₹1.02₹0.83+22.9%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹43.8 crNet profit₹11.1 crNet margin25.3%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025
3,874——
3.13.111.7
16016029.9
4,031——
174166151
—+10.0%—
82.475.568.8
47.4%45.6%45.7%
67.562.663.5
48.746.748.8
28.0%28.2%32.3%
₹4.47₹4.28₹4.48
—−4.3%—
—48.891.0
—−173−116
−124−124−25.1
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

GUJTHEM₹355.55

Gujarat Themis Biosyn Limited

· Pharma & Health
₹ CrorePeersRPGLIFEGUFICBIOORCHPHARMAUNICHEMLABFDCIOLCPMOREPENLABINNOVACAPMcap ₹3,874 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization——3,874.3
- Cash, Equiv & ST Investments11.73.13.1
+ Total Debt29.9159.9159.9
Enterprise Value——4,031.0
Revenue150.8165.8173.7
Growth %, YoY—+10.0—
EBITDA68.875.582.4
Margin %45.6545.5547.43
EBIT63.562.667.5
Net Income48.846.748.7
Margin %32.3428.1528.02
EPS, Adj (current shares)4.484.284.47
Growth %, YoY—-4.3—
Cash from Operations91.048.8—
Capital Expenditures-116.2-172.5—
Free Cash Flow-25.1-123.8-123.8
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Gujarat Themis Biosyn financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Gujarat Themis Biosyn (NSE: GUJTHEM) had a market capitalisation of ₹4,095 crore at the 29 October 2026 close (₹375.80 a share), a PE ratio of 84.1 on the last four quarters' profit and a price-to-book ratio of 14.23. In FY26 its consolidated net profit was ₹46.7 crore on revenue of ₹166 crore; in Q1 FY27 (April–June 2026) it was ₹11.1 crore, up 22.1% year on year. Its debt-to-equity ratio was 0.56 on 31 March 2026. Promoters held 59.33% of the shares on 30 September 2026.

Share price used
₹375.80 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Gujarat Themis Biosyn at a glance · consolidated

Market cap
₹4,095 Crat ₹375.80 · 29 Oct close
PE ratio (last 4 quarters)
84.187.7 on FY26 profit
Price to book (PB)
14.23book value ₹26.41 a share
ROE (FY26)
17.4%ROCE 17.8%
Debt to equity
0.56net debt ₹154 Cr
Promoter holding
59.33%−11.5 pts vs 30 Jun 202630 September 2026
Dividend yield
0.18%₹0.67 a share in 12 months
Net worth
₹288 Cr+15.9% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
−₹124 Cr

Questions

What is the Gujarat Themis Biosyn PE ratio today?

Gujarat Themis Biosyn's PE ratio is 84.1 at the 29 October 2026 close (₹375.80 a share): a market capitalisation of ₹4,095 crore divided by consolidated net profit of ₹48.7 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹46.7 crore) it is 87.7.

What is the Gujarat Themis Biosyn net worth?

Gujarat Themis Biosyn's net worth — shareholders' equity in its consolidated balance sheet — was ₹288 crore on 31 March 2026, up 15.9% from ₹248 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹4,095 crore at the 29 October 2026 close.

What is the Gujarat Themis Biosyn book value per share?

Gujarat Themis Biosyn's book value per share was ₹26.41 on 31 March 2026: shareholders' equity of ₹288 crore divided by the 10.9 crore shares in issue, up 15.9% from ₹22.79 a year earlier. The share price at the 29 October 2026 close was ₹375.80.

What is the Gujarat Themis Biosyn PB ratio (price to book value)?

Gujarat Themis Biosyn's price-to-book (PB) ratio is 14.23 at the 29 October 2026 close: a market capitalisation of ₹4,095 crore divided by shareholders' equity (book value) of ₹288 crore on 31 March 2026. That is a book value of ₹26.41 per share against a share price of ₹375.80.

What is the Gujarat Themis Biosyn ROE and ROCE?

In FY26, Gujarat Themis Biosyn's return on equity (ROE) was 17.4% and its return on capital employed (ROCE) was 17.8%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities).

What is the Gujarat Themis Biosyn dividend yield?

Gujarat Themis Biosyn's dividend yield is 0.18% at the 29 October 2026 close: dividends of ₹0.67 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹375.80. They were ₹0.67 on 23 September 2026.

What is the Gujarat Themis Biosyn market cap?

Gujarat Themis Biosyn's market capitalisation was ₹4,095 crore at the 29 October 2026 close: 10.9 crore shares at ₹375.80 each.

Is Gujarat Themis Biosyn debt free?

No. Gujarat Themis Biosyn had borrowings of ₹160 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.56. Its cash and current investments were ₹6.1 crore, so its net debt was ₹154 crore.

What is the Gujarat Themis Biosyn dividend in 2026 and its record date?

In 2026, Gujarat Themis Biosyn has declared one dividend: ₹0.67 with record date 23 September 2026.

What is the Gujarat Themis Biosyn debt to equity ratio?

Gujarat Themis Biosyn's debt-to-equity ratio was 0.56 on 31 March 2026: borrowings of ₹160 crore against total equity of ₹288 crore. A year earlier, on 31 March 2025, it was 0.12.

What is the Gujarat Themis Biosyn revenue and profit in FY26?

In FY26 (April 2025–March 2026), Gujarat Themis Biosyn's consolidated net profit was ₹46.7 crore, down 4.3% from ₹48.8 crore in FY25, on revenue from operations of ₹166 crore (up 10.0%).

When are the Gujarat Themis Biosyn next results?

Gujarat Themis Biosyn will announce its Q2 FY27 results (July–September 2026) on Wednesday, 4 November 2026, the date of the board meeting it has notified to the exchanges.

What is the Gujarat Themis Biosyn EPS?

Gujarat Themis Biosyn's basic earnings per share (EPS) were ₹4.28 in FY26, against ₹4.48 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹4.47.

What is the Gujarat Themis Biosyn promoter holding?

Promoters held 59.33% of Gujarat Themis Biosyn on 30 September 2026, down 11.53 percentage points from 70.86% the previous quarter and down 11.53 percentage points from 70.86% a year earlier, according to the shareholding pattern filed with NSE.

What is the Gujarat Themis Biosyn free cash flow?

In FY26, Gujarat Themis Biosyn generated ₹48.8 crore of cash from operations and spent ₹173 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹124 crore. In FY25 it was −₹25.1 crore.

What is the Gujarat Themis Biosyn shareholding pattern?

On 30 September 2026, Gujarat Themis Biosyn's shares were held by promoters 59.33%, foreign portfolio investors (FII/FPI) 3.80%, domestic institutions (DII) 12.65% (including mutual funds at 9.63%) and retail and other non-institutional investors 24.22%. Over the year, FII holding was up 0.85 percentage points from 2.95% and DII holding was up 11.48 percentage points from 1.17%.

How does Gujarat Themis Biosyn compare with its peers?

On FY26 consolidated figures, against RPG Life Sciences, Gufic Biosciences and Orchid Pharma: Gujarat Themis Biosyn's operating margin of 37.8% is the highest of the four (RPG Life Sciences 17.8%, Gufic Biosciences 12.8%, Orchid Pharma −0.8%; peer average 9.9%); its return on equity of 17.4% is the second highest of the four (RPG Life Sciences 20.3%, Gufic Biosciences 10.1%, Orchid Pharma 0.7%; peer average 10.4%).

How does the Gujarat Themis Biosyn PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit, Gujarat Themis Biosyn's PE ratio is 87.7, the second highest of the four: RPG Life Sciences 43.1, Gufic Biosciences 65.4 and Orchid Pharma 537.2, a peer average of 215.2. Each is the company's market capitalisation at that price divided by its FY26 net profit.

What are the Gujarat Themis Biosyn latest quarterly results?

Gujarat Themis Biosyn's latest results are for Q1 FY27 (April–June 2026), filed on 7 August 2026: consolidated net profit ₹11.1 crore, up 22.1% from ₹9.1 crore in Q1 FY26; revenue from operations ₹43.8 crore, up 22.1% year on year.

Gujarat Themis Biosyn vs RPG Life Sciences: how do they compare?

In FY26, Gujarat Themis Biosyn earned net profit of ₹46.7 crore on revenue of ₹166 crore, against ₹115 crore on ₹708 crore for RPG Life Sciences. Gujarat Themis Biosyn's operating margin was 37.8% (RPG Life Sciences 17.8%) and its return on equity 17.4% (RPG Life Sciences 20.3%). At the 29 October 2026 close, Gujarat Themis Biosyn's market capitalisation was ₹4,095 crore against ₹4,968 crore for RPG Life Sciences, and its PE ratio on FY26 profit 87.7 against 43.1.

Where do these Gujarat Themis Biosyn figures come from?

From Gujarat Themis Biosyn's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.